CATT Study Update 13: A First Peek

As reported by Andrew Pollack of the NYTimes, in a column published earlier today, the first results of the 1200 patient CATT Study (Comparison of AMD Treatments Trials), whose first-year results are scheduled for release at ARVO on Sunday afternoon, indicate equivalency between Avastin and Lucentis.

Speaking to two of the researchers involved in the study (and who presumably had access to the study results), Pollack basically said that the study will be interpreted in many ways, as some complicating factors may indicate that Lucentis is safer to use than Avastin.

Here are Pollack’s comments:

Test of Eye (Read more...)

Full Story →